

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2022/261243 A1

(43) International Publication Date
15 December 2022 (15.12.2022)

(51) International Patent Classification:

A61K 31/165 (2006.01) *C07D 209/424* (2006.01)
A61K 31/404 (2006.01) *A61P 35/00* (2006.01)

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2022/032718

(22) International Filing Date:

08 June 2022 (08.06.2022)

Published:

— with international search report (Art. 21(3))

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/208,882 09 June 2021 (09.06.2021) US

(71) Applicant: **EPIZYME, INC.** [US/US]; 400 Technology Square, 4th Floor, Cambridge, Massachusetts 02139 (US).

(72) Inventors: **RAIMONDI, Maria Alejandra**; 22 McBride Street, Jamaica Plain, Massachusetts 02130 (US). **TOTMAN, Jennifer Anne**; 52 Derby Road, Berlin, Massachusetts 01503 (US). **MOTWANI, Vinny**; 8 Ellis Street, Newton, Massachusetts 02464 (US). **COSMOPOULOS, Katherine Louise**; 85 Sharon Street, Medford, Massachusetts 02155 (US). **BRACH, Dorothy**; 27 Chatham Way, Lynnfield, Massachusetts 01940 (US). **DRANSFIELD, Daniel T.**; 14 George Street, Hanson, Massachusetts 02341 (US).

(74) Agent: **GROSS III, Michael F.** et al.; Sterne, Kessler, Goldstein & Fox P.L.L.C., 1100 New York Avenue, NW, Washington, District of Columbia 20005 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: COMBINATION THERAPIES WITH SETD2 INHIBITORS

(57) Abstract: The present disclosure provides SETD2 protein inhibitors, and methods, uses, compositions, and kits for treating diseases, disorders, or conditions in a subject with a SETD2 protein inhibitor and a Second Therapeutic Agent, wherein the Second Therapeutic Agent comprises one or more BTK inhibitors, one or more anti-CD20 monoclonal antibodies, one or more alkylating agents, one or more topoisomerase II inhibitors, one or more vinca alkaloids, one or more platinum-based drugs, one or more nucleoside anticancer agents, one or more PI3K inhibitors, one or more CDK4/6 inhibitors, one or more CARM1 inhibitors, one or more inhibitors of enzymes of DNA damage repair, one or more SYK inhibitors, or one or more MEK inhibitors, or a combination thereof.

WO 2022/261243 A1